Please use this identifier to cite or link to this item:
Title: Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.
Austin Authors: Paz-Ares, L;Doebele, R C;Farago, A F;Liu, S V;Chawla, S P;Tosi, D;Blakely, C M;Krauss, J C;Sigal, D;Bazhenova, L;John, Thomas ;Besse, B;Wolf, J;Seto, T;Chow-Maneval, E;Ye, C;Simmons, B;Demetri, G D
Affiliation: Hospital 12 de Octubre, Madrid, Spain
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
University of Colorado, Aurora, CO, USA
Massachusetts General Hospital, Boston, MA, USA
Georgetown University, Washington, DC, USA
Sarcoma Oncology Research Center, Santa Monica, CA, USA
Medical Oncology Departement, Institut du Cancer de Montpellier Inserm U1194, Montpellier University, Montpellier, France
University of California, San Francisco, CA, USA
University of Michigan, Ann Arbor, MI, USA
Scripps Clinic, La Jolla, CA, USA
University of California, San Diego, CA, USA
Gustave Roussy Cancer Campus, Villejuif, France
University Hospital of Cologne, Cologne, Germany
National Kyushu Cancer Center, Fukuoka, Japan
Ignyta, Inc., San Diego, CA, USA
Genentech, South San Francisco, CA, USA
Dana-Farber Cancer Institute, Boston, MA, USA
Issue Date: Apr-2019
Publication information: Annals of oncology : official journal of the European Society for Medical Oncology 2019; 30 Suppl 2: ii48-ii49
DOI: 10.1093/annonc/mdz063.011
PubMed URL: 32131246
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.